Revvity (RVTY) 2026 stock analysis: the PerkinElmer rebrand, a razor-blade recurring-revenue model across Diagnostics and Life Sciences, the newborn-screening franchise moat, and the China VBP and biotech-funding risks that move the story.
NTRA (Natera) 2026 stock outlook. A qualitative deep dive into Signatera tumor-informed MRD testing and Panorama prenatal (NIPT) recurring revenue, test volume and ASP dynamics, insurance coverage as the key lever, Guardant and Exact Sciences competition, and the path to profitability.
SD Biosensor (KOSPI 137310) 2026 stock analysis: normalizing revenue after the COVID rapid-test boom, the Meridian Bioscience acquisition, a large cash pile and capital allocation, POCT and molecular diagnostics diversification, and the Abbott/Roche competitive landscape.